Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$1.44 -1.4%	$1.59	$1.13 ▼ $2.66	$128.50M	2.61	395,763 shs	101,491 shs
HURA TuHURA Biosciences	$2.98 -0.7%	$2.59	$1.80 ▼ $8.40	$149.15M	0.04	307,175 shs	141,428 shs
KYTX Kyverna Therapeutics	$3.43 +3.9%	$3.44	$1.78 ▼ $8.78	$148.33M	3.05	371,038 shs	234,222 shs
SHLT SHL Telemedicine	$2.05	$2.05	$1.85 ▼ $4.45	$33.61M	0.11	11,919 shs	N/A

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	-5.81%	-0.68%	-5.19%	+5.04%	-18.44%
HURA TuHURA Biosciences	-2.91%	-7.69%	+14.50%	-9.37%	+299,999,900.00%
KYTX Kyverna Therapeutics	-6.78%	+9.27%	-15.38%	+49.32%	-52.72%
SHLT SHL Telemedicine	0.00%	0.00%	0.00%	0.00%	-44.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEN Compugen	1.8706 of 5 stars	3.5	3.0	0.0	0.0	2.3	0.0	0.0
HURA TuHURA Biosciences	1.793 of 5 stars	3.7	0.0	0.0	0.0	2.9	0.0	0.0
KYTX Kyverna Therapeutics	2.1742 of 5 stars	3.6	2.0	0.0	0.0	2.8	0.0	0.6
SHLT SHL Telemedicine	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$4.00	177.78% Upside
HURA TuHURA Biosciences	3.40	Buy	$12.67	325.06% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$15.60	354.81% Upside
SHLT SHL Telemedicine	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SHLT, KYTX, CGEN, and HURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	KYTX Kyverna Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$22.14M	5.80	N/A	N/A	$0.56 per share	2.57
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.38 per share	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$4.26 per share	N/A
SHLT SHL Telemedicine	$55.94M	0.60	$0.04 per share	54.03	$5.21 per share	0.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	-$14.23M	-$0.22	N/A	N/A	N/A	-87.45%	-34.77%	-16.82%	N/A
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	-248.79%	-150.83%	10/6/2025 (Estimated)
KYTX Kyverna Therapeutics	-$127.48M	-$3.68	N/A	N/A	N/A	N/A	-64.98%	-56.17%	N/A
SHLT SHL Telemedicine	-$7.06M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/24/2025 (Estimated)

Latest SHLT, KYTX, CGEN, and HURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HURA TuHURA Biosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A
8/12/2025	Q2 2025	KYTX Kyverna Therapeutics	-$1.00	-$0.97	+$0.03	-$0.97	N/A	N/A
8/6/2025	Q2 2025	CGEN Compugen	-$0.07	-$0.08	-$0.01	-$0.08	$3.95 million	$1.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
SHLT SHL Telemedicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	4.74	4.74
HURA TuHURA Biosciences	N/A	3.00	3.00
KYTX Kyverna Therapeutics	N/A	5.39	5.39
SHLT SHL Telemedicine	0.19	2.17	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
HURA TuHURA Biosciences	0.62%
KYTX Kyverna Therapeutics	18.08%
SHLT SHL Telemedicine	20.11%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
HURA TuHURA Biosciences	0.20%
KYTX Kyverna Therapeutics	N/A
SHLT SHL Telemedicine	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
HURA TuHURA Biosciences	N/A	50.05 million	43.59 million	N/A
KYTX Kyverna Therapeutics	96	43.25 million	N/A	Optionable
SHLT SHL Telemedicine	583	16.39 million	N/A	Not Optionable

SHLT, KYTX, CGEN, and HURA Headlines

Recent News About These Companies

SHL Telemedicine ADR Stock Price History

June 20, 2025 | investing.com

SHL Telemedicine Clarifies Voting Process for May 2025 AGM

May 20, 2025 | tipranks.com

SHL Telemedicine to Delist ADRs from Nasdaq to Cut Costs

March 11, 2025 | tipranks.com

SHLT SHL Telemedicine Ltd.

March 6, 2025 | seekingalpha.com

SHL Telemedicine Ltd (SHLTN)

January 23, 2025 | investing.com

SHL Telemedicine (NASDAQ:SHLT) Stock Quotes, Forecast and News Summary

December 18, 2024 | benzinga.com

DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

December 18, 2024 | businesswire.com

SHL Telemedicine (NASDAQ:SHLT) Stock, Short Interest Report

October 9, 2024 | benzinga.com

SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine

July 29, 2024 | 01net.it0

SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity

June 20, 2024 | businesswire.com

SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test

May 21, 2024 | businesswire.com

SHL Telemedicine Ltd ADR - New

May 17, 2024 | morningstar.comM

SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

May 16, 2024 | finance.yahoo.com

SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

May 16, 2024 | businesswire.com

SHL Telemedicine Ltd.: SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

April 17, 2024 | finanznachrichten.de

SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

April 17, 2024 | finance.yahoo.com

SHL Telemedicine Ltd. (SHLT)

April 16, 2024 | finance.yahoo.com

Telehealth clinical trial cuts hospital cardiac readmissions by 76%

April 11, 2024 | msn.com

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient Care

April 11, 2024 | finance.yahoo.com

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient Care

April 11, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SHLT, KYTX, CGEN, and HURA Company Descriptions

Compugen NASDAQ:CGEN

$1.44 -0.02 (-1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$1.46 +0.02 (+1.67%)

As of 04:19 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

TuHURA Biosciences NASDAQ:HURA

$2.98 -0.02 (-0.67%)

Closing price 04:00 PM Eastern

Extended Trading

$2.98 0.00 (-0.17%)

As of 04:10 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Kyverna Therapeutics NASDAQ:KYTX

$3.43 +0.13 (+3.94%)

Closing price 04:00 PM Eastern

Extended Trading

$3.44 +0.01 (+0.29%)

As of 04:10 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

SHL Telemedicine NASDAQ:SHLT

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time